Newsroom | 65718 results

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended September 30, 2025. Third Quarter 2025 Financial Results Net Income (Loss) from Continuing Operations Net income from continuing operations was $50 thousand, or $0.00 per basic and diluted common share, compared to a net loss of $567 thousand, or $0.05 per basic and diluted...

WESTERVILLE, Ohio--(BUSINESS WIRE)--agilon health, inc. (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, today announced that its management team will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025 at 3:00pm ET. Interested investors and other parties may listen to a simultaneous webcast of the presentation by visiting the “Events & Presentations” section of agilon health’s invest...

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the third quarter ended September 30, 2025. Recent Highlights • Third quarter 2025 net revenues of $10.4 million, a 27% increase over the prior year period • Core business (Dom...

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the third quarter ending September 30, 2025. “Our recent strategic financings further strengthen our balance sheet, significantly increase our cash runway, and allow us to accelerate our investment in preparing for the potential commercialization of MOLBREEVI,” said Matt Pauls, J.D., M.B.A., Chair and Chief Exe...

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today reported financial results for the third quarter ended September 30, 2025. “This quarter, we continued to execute across a diverse pipeline spanning multiple, potentially high impact projects in infectious diseases and oncology, leveraging our boron chemistry platform to ad...

ウィスコンシン州マディソン--(BUSINESS WIRE)--（ビジネスワイヤ） -- 米国食品医薬品局（FDA）は、プロメガの「OncoMate® MSI Dx分析システム」を承認しました。これは、マイクロサテライト安定（MSS：MSI-High［MSI-H］でないと定義）型子宮内膜がん患者を特定し、メルクの抗PD-1抗体療法KEYTRUDA®（ペムブロリズマブ）とエーザイが創製した経口マルチキナーゼ阻害薬LENVIMA®（レンバチニブ）の併用療法の治療候補となる患者を識別するために設計されており、プロメガにとって初のFDA承認を受けたコンパニオン診断となります。 OncoMate® MSI Dx分析システムは、腫瘍組織中のMSI（マイクロサテライト不安定性）ステータスを評価するPCRベースのアッセイです。MSIステータスは、治療方針の決定や子宮内膜がんにおける精密医療戦略の支援に活用することができます。 プロメガのグローバル臨床マーケット・ディレクターであるアロク・シャルマは次のように述べています。「今回の承認は、適切な患者に、適切なタイミングで、適切な治療を届けるうえで診断技...

BETHESDA, Md.--(BUSINESS WIRE)--BroadOak Capital Partners (“BroadOak”), a life-sciences focused investment and advisory firm, today announced multiple growth investments across its platform, highlighted by the first investment from BroadOak Fund VI, a growth equity financing in Azure Biosystems. This marks the third time over two decades that BroadOak has successfully partnered with the founders of Azure. BroadOak also formed and capitalized a special purpose vehicle to support Codis (formerly...

NASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE: HCA) is scheduled to present at the following healthcare conference: November 20, 2025 at 1:00pm CT at the 2025 Stephens Annual Investment Conference A link to the live audio webcast, where applicable, and copies of any related presentation materials will be made available at the Investor Relations section of the Company’s website, www.hcahealthcare.com. Dates and times may be subject to change, please check the conference schedule...

LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today hosted its 2025 Investor Day and presented its comprehensive strategic roadmap and long-range financial plan. “We are confident in our ability to deliver on the targets we outlined today. LivaNova’s talented team is focused on a revitalized innovation strategy and operational excellence,” said Vladimir Makatsaria, Chief Executive Officer of LivaNova. “The leadership positions we hold in our...

LAKE ZURICH, Ill.--(BUSINESS WIRE)--In the table of the release dated Nov 6, 2025, First Ship Date for Batch Number 6133388 should be 04/15/2025. The updated release reads:  FRESENIUS KABI ISSUES VOLUNTARY NATIONWIDE RECALL OF THREE LOTS OF FAMOTIDINE INJECTION, USP, 20 MG PER 2 ML (10 MG PER ML), 2 ML FILL IN A 2 ML VIAL DUE TO OUT-OF-SPECIFICATION ENDOTOXIN RESULTS IN CERTAIN RESERVE SAMPLES Fresenius Kabi, part of the global healthcare company Fresenius, and a leading provider of essential m...